
Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.
Experts preview key prostate cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.
As anticipation builds for the






